NCT05451849 2025-08-27A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing CancerTCR2 TherapeuticsPhase 1/2 Active not recruiting6 enrolled
NCT04521686 2025-06-27Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 MutationsEli Lilly and CompanyPhase 1 Active not recruiting200 enrolled
NCT06638931 2025-05-28ANTARESInstituto do Cancer do Estado de São PauloPhase 2 Active not recruiting28 enrolled
NCT05215574 2024-10-10Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid TumorsNGM Biopharmaceuticals, IncPhase 1 Active not recruiting130 enrolled
NCT04913337 2024-10-02Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor MalignanciesNGM Biopharmaceuticals, IncPhase 1/2 Active not recruiting179 enrolled
NCT05311618 2024-04-01Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid TumorsNGM Biopharmaceuticals, IncPhase 1 Active not recruiting71 enrolled